These results indicated that anti-PPM1A autoantibodies might not only serve as a diagnostic biomarker, but also associated with severity of sacroiliitis, and might be used as a predictor of response to anti-TNF therapy in AS patients. Here, PPM1A is linked to Sacroiliac arthritis.